Kawasaki disease, treatment

Intravenous Immune Globulin (IGIV) IGIV is a product derived from blood plasma from a donor pool similar to the immune globulin (IG) pool, but prepared so it is suitable for intravenous use. IGIV does not transmit infectious diseases. It is primarily used for replacement therapy in primary antibody-deficiency disorders, for the treatment of Kawasaki disease, immune thrombocytopenic purpura, hypogammaglobulinemia in chronic lymphocytic leukemia, and in some cases of HIV infection. 

Dajani A, Taubert K, Eerrieri P, et al. Treatment of acute streptococcal pharyngitis and prevention of rheumatic fever A statement for health professionals. Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease of the Council on Cardiovascular Disease in the Young, the American Heart Association. Pediatrics 1995 96 758-764. 

Suzuki, Y, Ichiyama, T., Ohsaki, A., et al. 2009. Anti-inflammatory effect of lalpha,25-dihy-droxyvitamin D(3) in human coronary arterial endothelial cells Implication for the treatment of Kawasaki disease. J Steroid Biochem Mol Biol, 113 134—8. 

M.P. Chu, D. Wang, Y.Y. Zhang, B.Q. Li, A.H. Zhou, X.W. Chen, Y Qian, Pachyman treatment improves CD4+CD25+ Treg counts and serum interleukin 4 and interferon y levels in a mouse model of Kawasaki disease. Mol. Medicine Reports, 5,1237-1240,2012. 

Kawakami T, Fujita A, Takeuchi S, Muto S, Soma Y. Drug-induced hypersensitivity syndrome drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease. J Am Acad Dermatol 2009 60(1) 146-9. 

---